


Accepted Manuscript

Title: New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells

Authors: Amir Amanzadeh, Vahid Molla-kazemiha, Saeed Samani, Mahdi Habibi-Anbouhi, Kayhan Azadmanesh, Mohsen Abolhassani, Mohammad Ali Shokrgozar



PII: S0145-2126(18)30008-0
DOI: <https://doi.org/10.1016/j.leukres.2018.01.007>
Reference: LR 5893

To appear in: *Leukemia Research*

Received date: 16-10-2017
Revised date: 29-12-2017
Accepted date: 14-1-2018

Please cite this article as: Amanzadeh Amir, Molla-kazemiha Vahid, Samani Saeed, Habibi-Anbouhi Mahdi, Azadmanesh Kayhan, Abolhassani Mohsen, Shokrgozar Mohammad Ali. New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells. *Leukemia Research* <https://doi.org/10.1016/j.leukres.2018.01.007>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells

Amir Amanzadeh ^a, Vahid Molla-kazemiha ^a, Saeed Samani ^d, Mahdi Habibi-Anbouhi ^a, Kayhan Azadmanesh ^b, Mohsen Abolhassani ^c, Mohammad Ali Shokrgozar ^a *

^a National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran

^b Department of Virology, Pasteur Institute of Iran, Tehran, Iran

^c Department of Immunology, Hybridoma Laboratory, Pasteur Institute of Iran, Tehran, Iran

^d Department of Tissue Engineering & Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

***Corresponding author:**

Mohammad Ali Shokrgozar

National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran

Tel: +98 21 64112300 Fax: +98 21 66492595

E-mail✉:shokrgozar1967@gmail.com (mashokrgozar@pasteur.ac.ir)*

Highlights

- Anti-CD44 monoclonal antibody improves “ATRA-FICZ”-induced APL (LSCs) cell differentiation.
- The “ATRA-FICZ-anti CD44 mAb” showed a synergistic effect in blocking CD44 antigen and triggering the maturation of NB4 cells.
- The highest anti-tumor activity of “ATRA-FICZ-anti CD44 mAb” were at 10 µg/ml of anti CD44 mAb in the triple combination.
- This triple compound may lead to novel clinical applications for APL and even other types of leukemia.

Download English Version:

<https://daneshyari.com/en/article/8453344>

Download Persian Version:

<https://daneshyari.com/article/8453344>

[Daneshyari.com](https://daneshyari.com)